Search clinical trials for: Liraglutide, Empagliflozin and Linagliptin

Total 471496 results

Medanta, The Medicity, India

Not yet recruiting

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)

Diabetes Mellitus | Kidney Transplant; Complications
Medanta, The Medicity, India

Recruiting

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus (EmLinaRenal)

Diabetes Mellitus | Kidney Transplant; Complications

India
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Nanjing First Hospital, Nanjing Medical University; Wuxi People's Hospital; Changzhou... and other collaborators

Recruiting

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial

Type 2 Diabetes Mellitus | Mild Cognitive Impairment

China
Alexandria University

Recruiting

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS)

Egypt
Kaiser Permanente
Patient-Centered Outcomes Research Institute; Henry Ford Health System; HealthPartners... and other collaborators

Recruiting

Comparison of Type 2 Diabetes Pharmacotherapy Regimens (ON TARGET DM)

Cardiovascular Diseases | Type 2 Diabetes Mellitus

United States
EMS

Not yet recruiting

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Type 2 Diabetes Mellitus
Oslo University Hospital
Vestre Viken Hospital Trust; University of Oslo; The Research Council of Norway; University Hospital, Akershus and other collaborators

Recruiting

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (DIASA3)

Glucose Metabolism Disorders | Impaired Glucose Tolerance | Insulin Sensitivity

Norway
Boehringer Ingelheim

Completed

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Boehringer Ingelheim

Completed

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Diabetes Mellitus, Type 2

United States, Canada, Thailand, Korea, Republic of, United Kingdom, China, Germany, Israel, Mexico, Argentina, Brazil, Colombia, Puerto Rico, Russian Federation
Boehringer Ingelheim

Completed

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Diabetes Mellitus, Type 2

Bulgaria, Czechia, Hungary, Poland, Russian Federation
RenJi Hospital

Terminated

Efficacy and Safety of Empagliflozin in NODAT

Kidney Transplant; Complications | New Onset Diabetes After Transplant

China
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Healthy

China
Khoo Teck Puat Hospital

Completed

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Type II Diabetes in Subjects BMI 27 to 32

Singapore
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
M.H.H. Kramer

Active, not recruiting

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES (RACELINES)

Type2 Diabetes

Netherlands
University of Pisa

Unknown

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. (UTI-flog)

Type 2 Diabetes | Urinary Tract Infections

Italy
University Hospital, Gentofte, Copenhagen
Eli Lilly and Company

Completed

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Type 2 Diabetes

Denmark
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Healthy

Germany
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes (4T)

Insulin Resistance | Prediabetic State

Mexico
Institut für Pharmakologie und Präventive Medizin
University of Erlangen-Nürnberg Medical School

Completed

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes (ELMI)

Diabetes Mellitus Type 2

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Steno Diabetes Center Copenhagen
University Medical Center Groningen

Withdrawn

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) (ROTATE-2)

Diabetic Nephropathy Type 2

Denmark
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Empa/Lina FDC Food Effect Study (Japan)

Healthy

Japan
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Unknown

Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV)

HIV/AIDS | HIV

United States
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
Profil Institut für Stoffwechselforschung GmbH

Completed

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Type 2 Diabetes Mellitus

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Healthy
Ann & Robert H Lurie Children's Hospital of Chicago
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (SGLT2I-IN-KIDS)

Chronic Kidney Diseases | Pediatric Kidney Disease

United States
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure
University Medical Center, Kazakhstan
Nazarbayev University; Astana Medical University; Ministry of Science and Higher... and other collaborators

Recruiting

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Metabolic Syndrome

Kazakhstan
China National Center for Cardiovascular Diseases

Recruiting

Use of SGLT2i in noHCM With HFpEF

Hypertrophic Cardiomyopathy | Heart Failure With Preserved Ejection Fraction

China
Hannover Medical School
Boehringer Ingelheim

Not yet recruiting

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) (EMPA-PKD)

Autosomal Dominant Polycystic Kidney
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
Matthieu Pelletier-Galarneau, MD MSc

Not yet recruiting

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging (SWEET-HEART)

Myocardial Suppression
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Handok Inc.

Not yet recruiting

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Healthy Volunteers
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Assiut University

Not yet recruiting

SGLT2 Inhibitors and Perioperative Period

Perioperative Complication
Damanhour University
Tanta University

Recruiting

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Coronary Artery Disease | Type 2 Diabetes

Egypt
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer

Search clinical trials for: Liraglutide, Empagliflozin and Linagliptin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations